Latest news with #DHODH
Yahoo
25-06-2025
- Health
- Yahoo
DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases
The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in targeting metabolic pathways in oncology and Immunology. While only two agents, leflunomide and teriflunomide, are currently approved, a growing clinical pipeline featuring candidates from companies like Immunic Therapeutics, Jabez Bioscience, and others suggests expanded therapeutic potential beyond traditional autoimmune indications. LAS VEGAS, June 25, 2025 /PRNewswire/ -- DelveInsight's DHODH Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as multiple sclerosis, ulcerative colitis, rheumatoid arthritis, NHL, and even viral infections. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging DHODH inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the DHODH Inhibitors Market Report As per DelveInsight's analysis, the total market size of DHODH inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as multiple sclerosis, ulcerative colitis, rheumatoid arthritis, NHL, and even viral infections. Leading DHODH inhibitors companies, such as Immunic Therapeutics, Aslan Pharmaceuticals, Jabez Bioscience, and others, are developing novel DHODH inhibitors that can be available in the DHODH inhibitors market in the coming years. Some of the key DHODH inhibitors in the pipeline include Vidofludimus Calcium (IMU-838), Farudodstat, JBZ-001, and others. Discover which indication is expected to grab the major DHODH inhibitors market share @ DHODH Inhibitors Market Report DHODH Inhibitors Market Dynamics The dihydroorotate dehydrogenase (DHODH) inhibitors market is witnessing growing interest due to the enzyme's critical role in the de novo pyrimidine biosynthesis pathway, which is essential for DNA and RNA synthesis. DHODH inhibitors block this mitochondrial enzyme, thereby curbing nucleotide synthesis and impeding the proliferation of rapidly dividing cells. This mechanism has significant therapeutic potential, particularly in oncology, autoimmune diseases, and viral infections. As a result, pharmaceutical companies are increasingly investing in the research and development of novel DHODH inhibitors, both as monotherapies and in combination with other agents. One of the major drivers of this market is the increased focus on targeted therapies in cancer treatment. Moreover, recent research indicates potential synergy when DHODH inhibitors are combined with other agents like BCL-2 or FLT3 inhibitors, opening avenues for combination therapies that may overcome resistance and improve patient outcomes. Additionally, the repurposing of DHODH inhibitors, such as leflunomide, initially developed for autoimmune diseases, has further catalyzed interest in this class of drugs. On the other hand, market growth is constrained by several challenges. The specificity and safety profiles of DHODH inhibitors remain areas of concern, as off-target effects or immunosuppressive consequences could limit their utility. Furthermore, competition from other targeted therapies and small molecules with established clinical efficacy can make market penetration difficult for newer DHODH inhibitors. Regulatory hurdles and the need for biomarker-driven patient stratification also add complexity to development and commercialization efforts. Looking forward, the DHODH inhibitor market is poised for steady growth, propelled by advancements in molecular biology, increasing unmet medical needs in oncology and autoimmune conditions, and the evolving landscape of precision medicine. Strategic partnerships, licensing deals, and successful late-stage trials will be critical in shaping the commercial success of emerging candidates. As the field matures, the development of next-generation DHODH inhibitors with enhanced selectivity and fewer side effects will be essential for capturing greater market share and achieving long-term clinical and commercial impact. DHODH Inhibitors Treatment Market In recent years, DHODH inhibitors have gained attention as a promising treatment strategy for chronic inflammatory and autoimmune disorders, including multiple sclerosis, ulcerative colitis, rheumatoid arthritis, and non-Hodgkin lymphoma. By targeting de novo pyrimidine synthesis, these agents effectively modulate immune responses, offering potential as disease-modifying therapies. Currently, only two DHODH inhibitors have been approved: leflunomide and its active metabolite, teriflunomide. Leflunomide, available generically, is mainly prescribed for rheumatoid arthritis, while teriflunomide, marketed as AUBAGIO, is approved for multiple sclerosis and became available in generic form in 2023. No other agents in this class have received regulatory approval so far. However, a number of novel candidates are undergoing clinical trials for autoimmune conditions, cancers, and viral infections, reflecting a growing interest in the target. Ongoing clinical results continue to demonstrate their potential, reinforcing the role of DHODH inhibitors as promising additions to the immunology drug pipeline. Learn more about the DHODH inhibitors @ DHODH Inhibitors Analysis Key Emerging DHODH Inhibitors and Companies Some of the emerging DHODH inhibitors in the pipeline include Vidofludimus Calcium (IMU-838) (Immunic Therapeutics), Farudodstat (Aslan Pharmaceuticals), JBZ-001 (Jabez Bioscience), and others. Vidofludimus calcium is an investigational oral small-molecule drug being developed as a next-generation therapy for multiple sclerosis and various chronic inflammatory and autoimmune conditions. It functions as a selective immune modulator by activating the neuroprotective transcription factor Nurr1 (nuclear receptor-related 1), which plays a role in promoting nerve cell protection. Additionally, the compound is a potent and selective inhibitor of the enzyme DHODH, essential for the metabolic processes of overactive immune and virus-infected cells. This dual mechanism contributes to its anti-inflammatory and antiviral properties. Also known as IMU-838, the drug is currently being evaluated in Phase III and Phase II clinical trials for relapsing and progressive forms of multiple sclerosis, respectively. It has shown therapeutic benefit in earlier Phase II trials across relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. JBZ-001 is another orally available small-molecule DHODH inhibitor, developed to interfere with the de novo pyrimidine nucleotide biosynthesis pathway, an essential process for the proliferation of cancer cells. By inhibiting DHODH, the pathway's rate-limiting enzyme, JBZ-001 has demonstrated cytotoxic potential against tumor cells, positioning it as a promising candidate in oncology. The compound, developed under Jabez Biosciences' translational research efforts, received FDA clearance for a commercial IND application in 2024 and is currently in Phase I trials for advanced solid tumors and hematologic cancers. The anticipated launch of these emerging therapies are poised to transform the DHODH inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the DHODH inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about DHODH inhibitors clinical trials, visit @ DHODH Inhibitors Treatment DHODH Inhibitors Overview DHODH inhibitors are a group of drugs that target and block the activity of the DHODH enzyme, which plays a vital role in the mitochondrial pathway responsible for de novo pyrimidine synthesis, crucial building blocks for DNA and RNA. By disrupting this process, these drugs reduce the supply of pyrimidines, thereby hindering DNA production and triggering cell cycle arrest, especially in fast-dividing cells. These agents are primarily used in conditions marked by excessive immune response or abnormal cell growth. In autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, they help restrain the proliferation of overactive immune cells. In cancer, DHODH inhibitors are under investigation for their ability to impede tumor growth, as cancer cells depend heavily on continuous nucleotide production. This targeted mode of action makes DHODH inhibitors a promising therapeutic option for managing various diseases driven by uncontrolled cell proliferation. DHODH Inhibitors Epidemiology Segmentation The DHODH inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for DHODH Inhibitors Total Eligible Patient Pool in Selected Indications for DHODH Inhibitors Total Treated Cases in Selected Indications for DHODH Inhibitors DHODH Inhibitors Report Metrics Details Study Period 2020–2034 DHODH Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Multiple sclerosis, ulcerative colitis, rheumatoid arthritis, NHL, and even viral infections Key DHODH Inhibitors Companies Immunic Therapeutics, Aslan Pharmaceuticals, Jabez Bioscience, and others Key DHODH Inhibitors Vidofludimus Calcium (IMU-838), Farudodstat, JBZ-001, leflunomide and teriflunomide (AUBAGIO, generic since 2023), and others Scope of the DHODH Inhibitors Market Report DHODH Inhibitors Therapeutic Assessment: DHODH Inhibitors current marketed and emerging therapies DHODH Inhibitors Market Dynamics: Conjoint Analysis of Emerging DHODH Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, DHODH Inhibitors Market Access and Reimbursement Discover more about DHODH inhibitors in development @ DHODH Inhibitors Clinical Trials Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Key Events 5. Epidemiology and Market Forecast Methodology 6. DHODH Inhibitors Market Overview at a Glance in the 7MM 6.1. Market Share (%) Distribution by Therapies in 2025 6.2. Market Share (%) Distribution by Therapies in 2034 6.3. Market Share (%) Distribution by Indications in 2025 6.4. Market Share (%) Distribution by Indications in 2034 7. DHODH Inhibitors: Background and Overview 7.1. Introduction 7.2. Potential of DHODH Inhibitors in Different Indications 7.3. Clinical Applications of DHODH Inhibitors 8. Target Patient Pool of DHODH Inhibitors 8.1. Assumptions and Rationale 8.2. Key Findings 8.3. Total Cases of Selected Indication for DHODH Inhibitors in the 7MM 8.4. Total Eligible Patient Pool of Selected Indication for DHODH Inhibitors in the 7MM 8.5. Total Treatable Cases in Selected Indications for DHODH Inhibitors in the 7MM 9. Emerging Therapies 9.1. Key Competitors 9.2. Vidofludimus Calcium (IMU-838): Immunic Therapeutics 9.2.1. Product Description 9.2.2. Other developmental activities 9.2.3. Clinical development 9.2.4. Safety and efficacy 9.3. JBZ-001: Jabez Bioscience 9.3.1. Product Description 9.3.2. Other developmental activities 9.3.3. Clinical development 9.3.4. Safety and efficacy List to be continued in the report 10. DHODH Inhibitors: Seven Major Market Analysis 10.1. Key Findings 10.2. Market Outlook 10.3. Conjoint Analysis 10.4. Key Market Forecast Assumptions 10.4.1. Cost Assumptions and Rebates 10.4.2. Pricing Trends 10.4.3. Analogue Assessment 10.4.4. Launch Year and Therapy Uptakes 10.5. Total Market Sizes of DHODH Inhibitors by Indications in the 7MM 10.6. The United States Market Size 10.6.1. Total Market Size of DHODH Inhibitors in the United States 10.6.2. Market Size of DHODH Inhibitors by Indication in the United States 10.6.3. Market Size of DHODH Inhibitors by Therapies in the United States 10.7. EU4 and the UK 10.7.1. Total Market Size of DHODH Inhibitors in EU4 and the UK 10.7.2. Market Size of DHODH Inhibitors by Indications in EU4 and the UK 10.7.3. Market Size of DHODH Inhibitors by Therapies in EU4 and the UK 10.8. Japan 10.8.1. Total Market Size of DHODH Inhibitors in Japan 10.8.2. Market Size of DHODH Inhibitors by Indications in Japan 10.8.3. Market Size of DHODH Inhibitors by Therapies in Japan 11. SWOT Analysis 12. KOL Views 13. Unmet Needs 14. Market Access and Reimbursement 15. Appendix 15.1. Bibliography 15.2. Report Methodology 16. DelveInsight Capabilities 17. Disclaimer 18. About DelveInsight Related Reports Ulcerative Colitis Market Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ulcerative colitis companies, including Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, NImmune, Merck, Mesoblast, among others. Non-Hodgkin's Lymphoma Market Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others. Multiple Sclerosis Market Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies, including Novartis, Sanofi, AB Science, Roche, Clene Nanomedicine, InnoCare Pharma, among others. Rheumatoid Arthritis Market Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies, including R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco (Oscotec), Hope Biosciences, Abivax, Mesoblast, Akros Pharma, Japan Tobacco, Pfizer, Philogen, AbbVie, Pfizer, SynAct Pharma, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-04-2025
- Business
- Yahoo
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO, Brian M. Strem, Ph.D., will provide an update on the progress of the Company's pipeline and its planned Phase 2 clinical trials of KIO-104 for the treatment of retinal inflammation and of KIO-301 for the treatment of retinitis pigmentosa. The presentation may be accessed live from the homepage of the investor relations section ( of Kiora's website and will be available for replay for 90 days on the investor relations "events" page ( About Kiora Pharmaceuticals Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH). In addition to news releases and SEC filings, we expect to post information on our website, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn, as well as to visit our website and/or subscribe to email alerts. Contacts: Investorsinvestors@ To view the source version of this press release, please visit Sign in to access your portfolio
Associated Press
03-03-2025
- Business
- Associated Press
Immunic to Participate in Scientific and Investor Conferences in March
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March: March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany. The presentations will be accessible on the 'Events and Presentations' section of Immunic's website at: Title: Orally Bioavailable RORγ/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity Presenting Author: Friedrich Hahn, Ph.D., Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany Abstract Talk: O 081 Session: Antiviral therapy and resistance I Date: March 6, 2025 Time: 9:30-9:45 am CET (3:30-3:45am ET) Title: Novel Vidofludimus-Based DHODH Inhibitors Containing Carboxylic Acid Bioisosters with Superior Broad-Spectrum Antiviral Activity Presenting Author: Alexandra Herrmann, Ph.D., Manager Translational Pharmacology, Immunic Abstract Talk: O 112 Session: Antiviral therapy and resistance II Date: March 7, 2025 Time: 11:00-11:15am CET (5:00-5:15am ET) March 10-12: Leerink Partners Global Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Wednesday, March 12, at 10:00 am ET during this conference in Miami. A webcast will be available on the 'Events and Presentations' section of Immunic's website at: Dr. Vitt, Glenn Whaley, Chief Financial Officer, and Jessica Breu, Vice President Investor Relations and Communications, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Leerink representative or Jessica Breu at: [email protected]. About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: Cautionary Statement Regarding Forward-Looking Statements This press release contains 'forward-looking statements' that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in scientific and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, including the ability to satisfy the minimum average price and trading volume conditions required to receive funding in tranche 2 and 3 of the January 2024 private placement, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned 'Risk Factors,' in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at or Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, Inc. +49 89 2080 477 09 [email protected] US IR Contact Rx Communications Group Paula Schwartz +1 917 633 7790 [email protected] US Media Contact KCSA Strategic Communications Caitlin Kasunich +1 212 896 1241
Yahoo
11-02-2025
- Business
- Yahoo
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
Encinitas, California--(Newsfile Corp. - February 11, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLARITY, a Phase 2 clinical trial to investigate KIO-104 in patients with retinal macular edema, a condition where build-up of fluid behind part of the retina can be associated with adverse vision changes. KIO-104 is a potent, locally delivered small molecule being developed as an alternative to steroids or systemic anti-inflammatory drugs, both of which have known shortcomings. KLARITY is a multi-center, open label study in up to 28 patients. The primary objective is to evaluate safety and tolerability of repeated doses of KIO-104 administered by standard intravitreal injection. Secondary endpoints will evaluate the magnitude of macula edema reduction, improvement in visual acuity and the systemic pharmacokinetic profile of KIO-104. The study will enroll patients with macular edema secondary to one of the following diseases: diabetic retinopathy, non-infectious uveitis, retinal vein occlusion, or post pseudophakic cataract surgery. The study will be performed in two parts as follows: Part A (Dose Optimization) will assess the safety and efficacy of three injections administered once every two weeks in 8 subjects. Cohort 1 of will receive 3.5 μg doses of KIO-104 while Cohort 2 will receive 10 μg doses of KIO-104. Part B (Cohort Expansion) will investigate different dosing regimens (2-week versus 4-week intervals) in the remaining subjects at a dose selected from Part A. "Our aim is to further demonstrate the therapeutic potential of KIO-104. The need for a local, steroid-sparing approach to treating conditions associated with retinal inflammation, including macular edema, remains at the forefront of clinical retinal research. We believe KIO-104 can fulfill that role and provide meaningful benefit to patients suffering from reduced vision due to macular edema," said Eric J. Daniels, MD, MBA, Chief Development Officer at Kiora. "Our drug is differentiated by its ease of delivery and the clinically validated immunomodulatory pathway upon which it acts. The class of compounds, DHODH inhibitors, are disease modifying, clinically effective and commercially successful as systemic treatments for multiple sclerosis and rheumatoid arthritis. We are now looking to expand the potential of this therapeutic class for use in inflammatory conditions of the eye." KIO-104 works by suppressing T cell numbers and function in the eye responsible for driving inflammation. Specifically, KIO-104 inhibits the mitochondrial enzyme, DHODH, which plays a crucial role in the synthesis of key building blocks of DNA and RNA. Through this nucleotide starvation, T cell replication is significantly impaired. In addition, these building blocks serve as key co-factors required for multiple T cell functions, including producing pro-inflammatory cytokines. About Kiora Pharmaceuticals Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH). In addition to news releases and SEC filings, we expect to post information on our website, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts. Forward-Looking Statements Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, Kiora's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the sufficiency of existing cash on hand to fund operations for specific periods, the projected cash runway, the ability to timely complete planned initiatives for 2024, including phase 2 clinical development of KIO-301 and KIO-104, the potential for KIO-301 to be the first treatment options for patients with inherited degenerative diseases like RP, Kiora's plans to further fund development of KIO-104, the potential for KIO-104 to reduce inflammation, the timing of topline results from clinical trials of KIO-104, the potential for KIO-104 to apply to other retinal inflammatory diseases, the anticipated readout dates for Kiora's clinical trials and their likelihood of success, and expected trends for research and development and general and administrative spending in 2024. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2024 or described in Kiora's other public filings including on Form 10-Q filed with the SEC on November 8, 2024. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law. ### Contact:investors@ To view the source version of this press release, please visit
